Literature DB >> 6253084

Association of polyoma T antigen and DNA with the nuclear matrix from lytically infected 3T6 cells.

A J Buckler-White, G W Humphrey, V Pigiet.   

Abstract

Nuclear matrix prepared from mouse 3T6 cells lytically infected with polyoma virus retained significant amounts of the 100K T antigen and intact viral genomes. Bound T antigen was resistant to the extraction by high salt (2 M NaCl), detergent (1% Triton X-100) and exhaustive DNAase treatment. Only conditions sufficient to disrupt the integrity of the matrix itself solubilized the matrix T antigen. During the time period of 16-30 hr after infection, both the accumulation (in microgram) and the incorporation of 35S-methionine into T antigen increased steadily in cell extracts to a peak at 26 hr and then declined. In contrast, the amount of labeled T antigen retained by the matrix was relatively constant over the same time period. Matrix-bound T antigen was more highly phosphorylated and newly synthesized compared with the extractable T antigen. Viral DNA steadily accumulates in nuclei and on the matrix from 18 to 30 hr after infection. The fraction of viral DNA retained by the matrix was greatest early in infection (25% at 16 hr), declining to less than 10% by 24 hr. These data are consistent with the existence of a fixed (and limited) number of sites for T antigen (more highly phosphorylated) on the matrix and implicate the nuclear matrix as a site of viral DNA replication and possibly encapsidation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253084     DOI: 10.1016/0092-8674(80)90152-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  36 in total

1.  In vivo and in vitro interaction between human transcription factor MOK2 and nuclear lamin A/C.

Authors:  Caroline Dreuillet; Jeanne Tillit; Michel Kress; Michèle Ernoult-Lange
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

2.  Chromosome-protein interactions in polyomavirus virions.

Authors:  Mariarosaria Carbone; Giuseppe Ascione; Silvia Chichiarelli; Marie-Isabelle Garcia; Margherita Eufemi; Paolo Amati
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I.

Authors:  D J Slamon; W J Boyle; D E Keith; M F Press; D W Golde; L M Souza
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  DNA sequence requirements for replication of polyomavirus DNA in vivo and in vitro.

Authors:  C Prives; Y Murakami; F G Kern; W Folk; C Basilico; J Hurwitz
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

5.  Nucleocytoplasmic traffic of CPEB1 and accumulation in Crm1 nucleolar bodies.

Authors:  Michèle Ernoult-Lange; Ania Wilczynska; Maryannick Harper; Christelle Aigueperse; François Dautry; Michel Kress; Dominique Weil
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

6.  Two phosphorylated subclasses of polyomavirus large T antigen that differ in their modes of association with the cell nucleus.

Authors:  G W Humphrey; V Pigiet
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

Review 7.  The nuclear matrix--its role in the spatial organization and replication of eukaryotic DNA.

Authors:  H M van der Velden; F Wanka
Journal:  Mol Biol Rep       Date:  1987       Impact factor: 2.316

8.  DNA polymerase alpha from the nuclear matrix of cells infected with simian virus 40.

Authors:  C Jones; R T Su
Journal:  Nucleic Acids Res       Date:  1982-09-25       Impact factor: 16.971

9.  Association between nuclear matrix and terminal transferase: an electron microscope immunocytochemical analysis.

Authors:  R Di Primio; O Trubiani; F J Bollum
Journal:  Histochemistry       Date:  1991

10.  Mutations in the VP1 coding region of polyomavirus determine differentiating stage specificity.

Authors:  L Ricci; R Maione; C Passananti; A Felsani; P Amati
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.